Content about Anti-diabetic drugs

DANBURY, Conn. The Food and Drug Administration has turned down an application for an insulin product made by Biodel, Biodel said.

The drug maker announced that it received a complete response letter from the FDA for Linjeta (human insulin [rDNA origin]) for the treatment of Type 1 and Type 2 diabetes.

BURLINGTON, Mass. Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug from Merck’s Januvia (sitagliptin) and Janumet (sitagliptin and metformin), according to a new report by market research firm Decision Resources.

INDIANAPOLIS The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli Lilly and two other companies, the companies said Tuesday.

Lilly, Amylin Pharmaceuticals and Alkermes said the FDA issued them a complete response letter for their application for Bydureon (exenatide), a once-weekly version of the Type 2 diabetes drug Byetta. A complete response letter means that the FDA has completed review of a regulatory application, but issues remain that preclude approval.

ST. PAUL, Minn. UltiMed, a company that makes insulin-delivery devices, has named a new executive.

The company announced the appointment of Brahim Zabeli as VP diabetes care for the U.S. market. In the new role, Zabeli will manage commercial activity, including sales, marketing and customer service.

Zabeli previously worked as director of trade and managed markets for medical supply company Becton, Dickinson & Co.

SILVER SPRING, Md. The Food and Drug Administration has moved to significantly restrict access to a controversial diabetes drug made by GlaxoSmithKline.

The agency said Thursday that it would restrict access to the Type 2 diabetes medication Avandia (rosiglitazone) in response to clinical study data suggesting that its use can increase the risk of heart attacks and strokes.

PARIS An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control in patients with diabetes, according to results of a late-stage clinical trial presented at a scientific meeting.

PRINCETON, N.J. Novo Nordisk has launched a mobile dosing app for healthcare professionals that prescribe the drug maker's insulin products.

NovoDose, which is available for download on iTunes, allows physicians to select the type of insulin they want to research and review suggested guidelines for dosing, titration and even blood glucose goals for their patients. The app also provides important safety information on the products, and only those who self-identify as healthcare professionals can download the app.